Industry & Research
-
What Is a Biosimilar? Understanding the Biologic Drug Market’s Version of Generic Competition
As the biologics era of medicine has matured — with monoclonal antibodies, recombinant proteins, and other complex biological drugs now representing a substantial share of total pharmaceutical spending — a parallel industry has emerged around biosimilars: FDA-approved copies of these biologic drugs designed to compete on price once the original product’s exclusivity expires. Understanding what…
-
Phylo Adds Chugai as Second Major Japanese Pharma Customer
Phylo, Inc., a private San Francisco Bay Area AI research lab, announced on August 4 that Chugai Pharmaceutical Co., Ltd. will deploy Biomni Lab, Phylo’s agentic AI platform for biomedical research, across its drug discovery workflows. Chugai is not a startup taking a flyer on unproven software: it is a Tokyo Stock Exchange-listed pharmaceutical company,…
-
What Is the Difference Between a Drug Target and a Biomarker? A Guide for Biotech Investors
Two terms that appear in almost every substantive description of a biotech company’s drug development program are drug target and biomarker. They are related but distinct — and confusing the two is one of the most common sources of misinterpretation when retail investors read clinical trial descriptions, pipeline summaries, or drug mechanism explanations. Understanding the…
-
What Is Preclinical Research? The Science That Happens Before Human Trials
Every drug that has ever entered a human clinical trial first passed through a preclinical research phase — a body of laboratory and animal studies conducted before any human being receives the compound. Preclinical research is where most drugs fail, often silently, without ever generating a press release or a stock move. For investors in…
-
Small Molecules vs. Biologics: What Every Biotech Investor Needs to Know
When you read about a biotech company’s pipeline, every drug falls into one of two fundamental categories: a small molecule or a biologic. This distinction affects how the drug is manufactured, how it is delivered to patients, how it is regulated by the FDA, how long it retains market exclusivity, and ultimately how much revenue…
-
What Is a Platform Technology in Biotech? Why It Matters More Than a Single Drug
When analysts describe a biotech company as a ‘platform company,’ they are saying something specific and important about how the business is valued. A platform technology is not just a drug — it is a repeatable, modular approach to generating drug candidates that can be applied across multiple disease targets. Platform companies are valued differently…